BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33550182)

  • 1. Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity.
    Xu B; Wang ZP; Liu Q; Yang X; Li X; Huang D; Qiu Y; Tam KY; Zhang SL; He Y
    Eur J Med Chem; 2021 Mar; 214():113225. PubMed ID: 33550182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of dual inhibitors targeting pyruvate dehydrogenase kinases and human lactate dehydrogenase A: High-throughput virtual screening, synthesis and biological validation.
    Xiang S; Huang D; He Q; Li J; Tam KY; Zhang SL; He Y
    Eur J Med Chem; 2020 Oct; 203():112579. PubMed ID: 32688200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.
    Zhang SL; Yang Z; Hu X; Tam KY
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3441-3445. PubMed ID: 30266541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cytotoxicity screening to identify novel anti-osteosarcoma therapeutics targeting pyruvate dehydrogenase kinase 2.
    Cao W; Wang Z; Han X; Liu J; Wang W
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126665. PubMed ID: 31495556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
    Wu DM; Wang YJ; Fan SH; Zhang ZF; Shan Q; Lu J; Chen GQ; Zheng YL
    Eur J Med Chem; 2019 Feb; 164():252-262. PubMed ID: 30597326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
    Guo F; Zhao S; Li X
    Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of mitochondria-targeted pyruvate dehydrogenase kinase 1 inhibitors with improved selectivity and antiproliferative activity.
    Xu B; Yu Z; Xiang S; Li Y; Zhang SL; He Y
    Eur J Med Chem; 2018 Jul; 155():275-284. PubMed ID: 29890389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.
    Sestito S; Bacci A; Chiarugi S; Runfola M; Gado F; Margheritis E; Gul S; Riveiro ME; Vazquez R; Huguet S; Manera C; Rezai K; Garau G; Rapposelli S
    Eur J Med Chem; 2021 Dec; 226():113895. PubMed ID: 34624821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological impact and therapeutic potential of a novel camptothecin derivative (FLQY2) in pancreatic cancer through inactivation of the PDK1/AKT/mTOR pathway.
    Wang W; Xiong H; Li L; Hu X; Zhuang W; Li J; Sun X; Yu Y; Yu Y; Guo Y; Wang Y; Wang R; Wang H; Li Q
    Bioorg Chem; 2024 Jul; 148():107436. PubMed ID: 38735265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
    Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
    Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
    Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
    Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives.
    Yu Z; Chen Z; Su Q; Ye S; Yuan H; Kuai M; Lv M; Tu Z; Yang X; Liu R; Hu G; Li Q
    Bioorg Med Chem; 2019 Mar; 27(6):944-954. PubMed ID: 30777660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands.
    Ghinet A; Thuru X; Floquet E; Dubois J; Farce A; Rigo B
    Bioorg Chem; 2020 Mar; 96():103643. PubMed ID: 32035298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
    Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.